Similarly, the subgroup analysis of tumors stratified by cancer type again demonstrated a significant association between CD147/EMMPRIN overexpression and adverse outcome of PFS/MFS/RFS in breast carcinoma (meta-HR = 2.50; 95% CI: 1.63–3.83) and ovarian cancer (meta-HR = 1.72; 95% CI: 1.23–2.40) in the multivariate model and renal cell carcinoma (meta-HR = 1.58; 95% CI: 1.34–1.85) in the univariate model. The gene discussed is BSG; the disease is renal cell carcinoma.